Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma

Molecular Medicine

Volumn 22, Issue , 2016, Pages 694-704

  Horenstein, Alberto L ^a,b   Quarona, Valeria ^a   Toscani, Denise ^c   Costa, Federica ^c   Chillemi, Antonella ^a   Pistoia, Vito ^d   Giuliani, Nicola ^c   Malavasi, Fabio ^a,b,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADENOSINE; CD203 ALPHA ANTIGEN; CD38 ANTIGEN; CD39 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; NUCLEOTIDASE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CELL DIFFERENTIATION; CELL POPULATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NUCLEOTIDE METABOLISM; OSTEOBLAST; OSTEOCLAST; PH; PILOT STUDY; PROTEIN EXPRESSION; SEX RATIO; STEM CELL NICHE; VERY ELDERLY;

EID: 85009730062     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2016.00198     Document Type: Article

References (40)

1. Palumbo A, Anderson K. (2011) Multiple myeloma. N. Engl. J. Med. 364:1046–60.
2. Abe M, et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104:2484–91.
3. Harris AL. (2002) Hypoxia—a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38–47.
4. Storti P, et al. (2013) Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 27:1697–706.
5. Vander Heiden MG, Cantley LC, Thompson CB. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–33.
6. Horenstein AL, et al. (2015) NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model. Cells 4:520–37.
7. Quarona V, et al. (2015) Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann. N. Y. Acad. Sci. 1335:10–22.
8. Penuela S, Gehi R, Laird DW. (2013) The biochemistry and function of pannexin channels. Biochim. Biophys. Acta. 1828:15–22.
9. Horenstein AL, et al. (2013) A CD38/CD203a/ CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2:e26246.
10. Malavasi F, et al. (2008) Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88:841–86.
11. Junger WG. (2011) Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11:201–12.
12. Morandi F, et al. (2015) A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget 6:25602–18.
13. Agarwal A, Ghobrial IM. (2013) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin. Cancer Res. 19:985–94.
14. Horenstein AL, Durelli I, Malavasi F. (2005) Purification of clinical-grade monoclonal antibodies by chromatographic methods. Methods Mol. Biol. 308:191–208.
15. Pegoraro L, et al. (1989) The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood 73:1020–7.
16. Paiva B, et al. (2014) Multiparameter flow cytometry for the identification of the Waldenstrom’s clone in IgM-MGUS and Waldenstrom’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 28:166–73.
17. Greipp PR, et al. (2005) International staging system for multiple myeloma. J. Clin. Oncol. 23:3412–20.
18. Toscani D, et al. (2015) Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity. In: 57th ASH Annual Meeting and Exposition. Blood, Orlando, FL, p. 2959.
19. Morandi F, et al. (2015) CD56brightCD16-NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. J. Immunol. 195:965–72.
20. Graeff RM, Walseth TF, Fryxell K, Branton WD, Lee HC. (1994) Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J. Biol. Chem. 269:30260–7.
21. Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H. (2011) Flavonoids as inhibitors of human CD38. Bioorg. Med. Chem. Lett. 21:3939–42.
22. Goding JW. (2000) Ecto-enzymes: physiology meets pathology. J. Leukoc. Biol. 67:285–311.
23. Graeff R, Liu Q, Kriksunov IA, Hao Q, Lee HC. (2006) Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine nicotinic acid adenine dinucleotide phosphate (NAADP) synthesis and hydrolysis activities. J. Biol. Chem. 281:28951–7.
24. Yegutkin GG. (2014) Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit. Rev. Biochem. Mol. Biol. 49:473–97.
25. Leal DB, et al. (2005) Characterization of NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes. Biochim. Biophys. Acta. 1721:9–15.
26. Vaupel P, Mayer A. (2016) Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. Adv. Exp. Med. Biol. 876:177–83.
27. Sitkovsky M, Ohta A. (2013) Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J. Mol. Med. (Berl) 91:147–55.
28. Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE. (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors— an update. Pharmacol. Rev. 63:1–34.
29. Reagan MR, Ghobrial IM. (2012) Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer. Res. 18:342–9.
30. Buque A, et al. (2016) - Trial Watch - Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 5.
31. Chillemi A, et al. (2014) CD38 and bone marrow microenvironment. Front. Biosci. (Landmark Ed) 19:152–62.
32. Cekic C, Linden J. (2016) Purinergic regulation of the immune system. Nat. Rev. Immunol. 16:177–92.
33. Kaunitz JD, Yamaguchi DT. (2008) TNAP, TrAP, ecto-purinergic signaling, and bone remodeling. J. Cell. Biochem. 105:655–62.
34. Utting JC, Flanagan AM, Brandao-Burch A, Orriss IR, Arnett TR. (2010) Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem. Funct. 28:374–80.
35. Chillemi A, et al. (2015) Generation and characterization of microvesicles after daratumumab interaction with myeloma cells. In: 57th ASH Annual Meeting and Exposition. Blood, Orlando, FL, p. 1849.
36. Rak J. (2015) Cancer: Organ-seeking vesicles. Nature 527:312–4.
37. Kumar S, Kimlinger T, Morice W. (2010) Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract. Res. Clin. Haematol. 23:433–51.
38. van de Donk NW, et al. (2016) Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:681–95.
39. Lonial S, Durie B, Palumbo A, San-Miguel J. (2016) Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 30:526–35.
40. Young A, Mittal D, Stagg J, Smyth MJ. (2014) Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4:879–88.